Free Trial
NASDAQ:EVLO

Evelo Biosciences (EVLO) Stock Price, News & Analysis

$0.06
0.00 (0.00%)
(As of 06/20/2024 ET)
Today's Range
$0.06
$0.06
50-Day Range
$0.00
$0.06
52-Week Range
$0.00
$13.93
Volume
N/A
Average Volume
330 shs
Market Capitalization
$1.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
EVLO stock logo

About Evelo Biosciences Stock (NASDAQ:EVLO)

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

EVLO Stock Price History

EVLO Stock News Headlines

Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
FMR LLC Reduces Stake in Evelo Biosciences Inc
Evelo Biosciences Inc EVLO
Q3 2023 Horizon Technology Finance Corp Earnings Call
Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug Study
Evelo drops as mid-stage trial for psoriasis drug fails
Evelo Biosciences shares tank 46% after trial failure
See More Headlines
Receive EVLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/27/2021
Today
6/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EVLO
Fax
N/A
Employees
66
Year Founded
N/A

Profitability

Net Income
$-114,530,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.92) per share

Miscellaneous

Free Float
18,789,000
Market Cap
$1.14 million
Optionable
No Data
Beta
1.75
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Key Executives

  • Mr. Craig R. Jalbert CIRA (Age 62)
    President, Secretary, Principal Executive, Financial and Accounting Officer & Director
  • Dr. Chun Zhang Ph.D.
    Chief Technical Operations & Quality Officer
  • Dr. Mark Bodmer Ph.D. (Age 66)
    Chief Scientific Officer and President of Research & Development
    Comp: $668.8k
  • Ms. Jessica Cotrone
    VP & Head of Communications
  • Ms. Leslie Wardwell-Scott Ph.D.
    VP and Head of Corporate Development & Strategic Integration
  • Dr. Andrea Itano Ph.D.
    Head of Research
  • Dr. Duncan McHale M.D. (Age 57)
    MBBS, Ph.D., Chief Medical Officer
    Comp: $661.97k
  • Mr. Douglas Maslin
    Senior Director & Immunology Clinical Lead

EVLO Stock Analysis - Frequently Asked Questions

Should I buy or sell Evelo Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EVLO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EVLO, but not buy additional shares or sell existing shares.
View EVLO analyst ratings
or view top-rated stocks.

How have EVLO shares performed in 2024?

Evelo Biosciences' stock was trading at $0.0615 at the beginning of the year. Since then, EVLO shares have decreased by 2.4% and is now trading at $0.06.
View the best growth stocks for 2024 here
.

How were Evelo Biosciences' earnings last quarter?

Evelo Biosciences, Inc. (NASDAQ:EVLO) released its quarterly earnings results on Wednesday, October, 27th. The company reported ($12.60) earnings per share for the quarter, missing the consensus estimate of ($10.80) by $1.80. During the same quarter last year, the company posted ($9.00) earnings per share.

When did Evelo Biosciences' stock split?

Evelo Biosciences shares reverse split before market open on Friday, June 30th 2023. The 1-20 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Evelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX).

When did Evelo Biosciences IPO?

Evelo Biosciences (EVLO) raised $85 million in an initial public offering (IPO) on Wednesday, May 9th 2018. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

How do I buy shares of Evelo Biosciences?

Shares of EVLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EVLO) was last updated on 6/21/2024 by MarketBeat.com Staff

From Our Partners